142253-57-4 Usage
General Description
(1-(tert-Butoxycarbonyl)azetidin-3-yl)-methyl-methanesulfonate is a chemical compound used in organic synthesis and pharmaceutical research. It is a derivative of azetidine, a four-membered ring compound containing a nitrogen atom. The tert-butoxycarbonyl (Boc) group is a protecting group commonly used in organic chemistry to temporarily mask reactive functional groups. The methanesulfonate group is a leaving group that can be displaced by nucleophiles in substitution reactions. (1-(tert-Butoxycarbonyl)azetidin-3-yl)-methyl-methanesulfonate is likely used as a precursor for the synthesis of other compounds with desired properties for pharmaceutical applications, such as antiviral or antibacterial activity. Its specific properties and applications would need to be elucidated through further research and investigation.
Check Digit Verification of cas no
The CAS Registry Mumber 142253-57-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,2,5 and 3 respectively; the second part has 2 digits, 5 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 142253-57:
(8*1)+(7*4)+(6*2)+(5*2)+(4*5)+(3*3)+(2*5)+(1*7)=104
104 % 10 = 4
So 142253-57-4 is a valid CAS Registry Number.
142253-57-4Relevant articles and documents
INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER
-
Page/Page column 71; 85; 88; 113, (2022/02/06)
The present invention relates to indole derivatives of formula (I') as CK2 inhibitor and pharmaceutical compositions comprising the same. The present invention further relates to the use of such compounds of formula (I) for use for preventing and/or treating a cancer.
AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR
-
Paragraph 0148, (2021/05/29)
A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.
BICYCLIC INHIBITORS OF HISTONE DEACETYLASE
-
Paragraph 00257, (2020/02/06)
Provided herein are compounds of Formula I and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with histone deacetylases (HDAC).
